Diabetes & Endocrinology Clinical Trials Update: Week 25, 2026

Published June 19, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before

This Phase 3 study looked at insulin icodec, a new insulin treatment given once a week, compared to the usual daily insulin shots for people with type 2 diabetes who have never used insulin before. With over 1000 participants from several countries, the study showed that this weekly insulin could make managing diabetes easier by reducing the number of injections and simplifying dose adjustments. If approved, this treatment may offer a more convenient option for people starting insulin therapy.

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

This Phase 3 trial tested IcoSema, a new weekly injection that combines insulin icodec and semaglutide, against semaglutide alone in people with type 2 diabetes. The study found that IcoSema may better control blood sugar levels compared to current weekly treatment. This could provide patients with a more effective once-weekly medicine, reducing the number of injections while improving diabetes management.

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

This ongoing Phase 3 trial is evaluating aleniglipron, an oral medication, for adults who are overweight or have obesity along with related health problems. With plans to include 3600 participants in the United States, this study aims to see if aleniglipron can help people lose weight safely when combined with diet and exercise. If successful, it may offer a new long-term option to support weight management.

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

This Phase 3 study focuses on aleniglipron in adults who are overweight or have obesity and also have type 2 diabetes. The trial is testing whether this oral medication can help control both weight and blood sugar levels over a 76-week period. Results from this study could provide a new treatment choice for people managing both conditions simultaneously.

A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)

This study compared insulin icodec, given once weekly, to daily insulin degludec in adults with type 2 diabetes who have not used insulin before. The results, now available, suggest that insulin icodec could be a simpler and less frequent injection option while still effectively controlling blood sugar. This may help people new to insulin treatment have an easier start in managing their diabetes.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.